Parima Hirunwiwatkul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Parima Hirunwiwatkul has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Supaporn Krittanupong
Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok 10330, Thailand
3 shared publications- Supharat Jariyakosol
Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
3 shared publications - Wasee Tulvatana
Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
3 shared publications Buravej Assavapongpaiboon
Department of Ophthalmology, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand
2 shared publicationsJiruth Sriratanaban
Affiliation Preventive and Social Medicine Department, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
2 shared publicationsNiphon Chirapapaisan
Affiliation Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
2 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-8
Tetracaine Eye Drops as a Preemptive Topical Skin Anesthesia for Botulinum Toxin Type A Injections in Blepharospasm Patients: A Randomized Controlled Trial
Purpose: To evaluate the efficacy and safety of topical tetracaine eye drops as a preemptive skin anesthetic during botulinum toxin type A injection in blepharospasm patients. Patients and Methods: A double-blind, split-face randomized controlled trial was conducted in 17 participants diagnosed with benign essential blepharospasm between November 2023 and July 2024. Each patient received randomized treatment on opposite sides of the face: a cotton pad soaked with 5 mL of 0.5% tetracaine ophthalmic solution on one side and normal saline solution on the other, for 30 minutes. The cotton pad temperature, the injection dose, and the techniques were controlled on each side. A single neuro-ophthalmologist performed the injection. Pain scores were immediately rated after the injection, using a numeric rating scale from 0 to 10. Jankovic rating scale and complications were assessed on the day of injection, then 1 month and 3 months after injection. Results: The numeric rating scale on the side receiving topical 0.5% tetracaine eye drops was significantly lower than the side receiving topical normal saline solution (4.56 ± 2.63 vs 6.71 ± 2.54, p = 0.013). There were no significant differences in the Jankovic rating scale, cotton pad temperature, bleeding at the injection site, and other complications between the two groups. Conclusion: The application of 0.5% tetracaine ophthalmic solution as a preemptive topical skin anesthesia can decrease pain during botulinum toxin type A injection for blepharospasm patients without affecting the efficacy or producing any significant complications.
- 1 May 2026
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-8
Open AccessTetracaine Eye Drops as a Preemptive Topical Skin Anesthesia for Botulinum Toxin Type A Injections in Blepharospasm Patients: A Randomized Controlled Trial
Purpose: To evaluate the efficacy and safety of topical tetracaine eye drops as a preemptive skin anesthetic during botulinum toxin type A injection in blepharospasm patients. Patients and Methods: A double-blind, split-face randomized controlled trial was conducted in 17 participants diagnosed with benign essential blepharospasm between November 2023 and July 2024. Each patient received randomized treatment on opposite sides of the face: a cotton pad soaked with 5 mL of 0.5% tetracaine ophthalmic solution on one side and normal saline solution on the other, for 30 minutes. The cotton pad temperature, the injection dose, and the techniques were controlled on each side. A single neuro-ophthalmologist performed the injection. Pain scores were immediately rated after the injection, using a numeric rating scale from 0 to 10. Jankovic rating scale and complications were assessed on the day of injection, then 1 month and 3 months after injection. Results: The numeric rating scale on the side receiving topical 0.5% tetracaine eye drops was significantly lower than the side receiving topical normal saline solution (4.56 ± 2.63 vs 6.71 ± 2.54, p = 0.013). There were no significant differences in the Jankovic rating scale, cotton pad temperature, bleeding at the injection site, and other complications between the two groups. Conclusion: The application of 0.5% tetracaine ophthalmic solution as a preemptive topical skin anesthesia can decrease pain during botulinum toxin type A injection for blepharospasm patients without affecting the efficacy or producing any significant complications.
- Open Access
- 1 October 2025
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 17, 717-728
Budget Impact Analysis of Botulinum Toxin Type A for Patients with Severe Blepharospasm in Thailand
Objective: Severe blepharospasm is a disabling neurological condition that significantly affects patients’ quality of life. Botulinum toxin type A (BoNT-A) is considered the standard treatment due to its targeted therapeutic effect and fewer systemic side effects compared to oral medications. However, its high cost poses a barrier to access within Thailand’s healthcare system. This study aimed to assess the budget impact of introducing BoNT-A treatment (Onabotulinumtoxin A and Abobotulinumtoxin A) compared with current oral medications for severe blepharospasm in Thailand. Methods: A budget impact model was developed from the perspective of Thailand’s healthcare system over a 5-year time horizon. The current scenario (oral medications use) was compared with a new scenario involving BoNT-A treatment. The costs considered included drug acquisition, outpatient visits, and accident-related injuries. The base-case assumed gradual uptake of BoNT-A (30% in year 1, 50% in year 2, and 100% from year 3). Sensitivity analyses explored full uptake from year 1, no dose sharing, and inclusion of injury-related costs. Results: Excluding injury-related costs, the 5-year net budget impact (NBI) was 7.91 million THB (223,040 USD) for onabotulinumtoxin A and 7.27 million THB (205,064 USD) for abobotulinumtoxin A. Including injury-related costs reduced the NBI to 4.20 million THB (118,564 USD) and 3.57 million THB (100,588 USD), respectively. Without dose sharing, the NBI rose significantly, reaching 40.5 million THB (1.14 million USD) for abobotulinumtoxin A. Conclusion: BoNT-A treatment increases healthcare costs, primarily due to drug costs. However, reduced injury costs and dose-sharing strategies may enhance affordability and support BoNT-A’s inclusion in Thailand’s National List of Essential Medicine.
- 1 October 2025
- Published by Taylor & Francis in ClinicoEconomics and Outcomes Research
- Vol. ume 17, 717-728
Open AccessBudget Impact Analysis of Botulinum Toxin Type A for Patients with Severe Blepharospasm in Thailand
Objective: Severe blepharospasm is a disabling neurological condition that significantly affects patients’ quality of life. Botulinum toxin type A (BoNT-A) is considered the standard treatment due to its targeted therapeutic effect and fewer systemic side effects compared to oral medications. However, its high cost poses a barrier to access within Thailand’s healthcare system. This study aimed to assess the budget impact of introducing BoNT-A treatment (Onabotulinumtoxin A and Abobotulinumtoxin A) compared with current oral medications for severe blepharospasm in Thailand. Methods: A budget impact model was developed from the perspective of Thailand’s healthcare system over a 5-year time horizon. The current scenario (oral medications use) was compared with a new scenario involving BoNT-A treatment. The costs considered included drug acquisition, outpatient visits, and accident-related injuries. The base-case assumed gradual uptake of BoNT-A (30% in year 1, 50% in year 2, and 100% from year 3). Sensitivity analyses explored full uptake from year 1, no dose sharing, and inclusion of injury-related costs. Results: Excluding injury-related costs, the 5-year net budget impact (NBI) was 7.91 million THB (223,040 USD) for onabotulinumtoxin A and 7.27 million THB (205,064 USD) for abobotulinumtoxin A. Including injury-related costs reduced the NBI to 4.20 million THB (118,564 USD) and 3.57 million THB (100,588 USD), respectively. Without dose sharing, the NBI rose significantly, reaching 40.5 million THB (1.14 million USD) for abobotulinumtoxin A. Conclusion: BoNT-A treatment increases healthcare costs, primarily due to drug costs. However, reduced injury costs and dose-sharing strategies may enhance affordability and support BoNT-A’s inclusion in Thailand’s National List of Essential Medicine.
- Open Access
- 21 April 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (4) , e0319926
Cost-utility analysis of botulinum toxin type A versus oral drug treatment in patients with severe blepharospasm in Thailand
Background: Blepharospasm is a chronic facial movement disorder affecting a person’s ability to work, causing depression, pain, and a reduced quality of life (QoL). Botulinum toxin type A (BoNT-A) treatment can improve these conditions; however, its cost remains a significant barrier for inclusion of this indication into the Thai National List of Essential Medicine. Objectives: This study aimed to assess the cost-effectiveness of onabotulinumtoxinA (onaBoNT-A) and abobotulinumtoxinA (aboBoNT-A) treatment compared to oral medication treatment in patients with severe blepharospasm from a societal perspective. Methods: A cost-utility analysis using a two-part model was conducted to analyze lifetime costs and quality-adjusted life-years (QALYs). Inputs were mainly obtained from real-world evidence of 159 Thai patients with blepharospasm. Costs and outcomes were discounted at 3% annually and presented as 2023 value. Incremental cost-effectiveness ratios (ICERs) were estimated. Deterministic and probabilistic sensitivity analyses were also conducted. Results: In comparison to standard oral medication, both onaBoNT-A and aboBoNT-A incurred greater lifetime cost (3,055 USD, 2,889 USD vs 1,926 USD) while gaining additional QALYs (6.94 years, 6.94 years vs 6.53 years). The estimated ICERs were 2,722 USD/QALY for onaBoNT-A and 2,323 USD/QALY for aboBoNT-A. Utility and cost of BoNT-A were important determinants in the sensitivity analysis. Conclusion: Among patients with severe blepharospasm, both onaBoNT-A and aboBoNT-A were considered a cost-effective strategy under the Thai willingness to pay threshold of 4,613 USD/QALY. Having aboBoNT-A was slightly more favorable due to lower cost, using a conversion ratio of 1U of onaBoNT-A: 3U of aboBoNT-A.
- 21 April 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (4) , e0319926
Open AccessCost-utility analysis of botulinum toxin type A versus oral drug treatment in patients with severe blepharospasm in Thailand
Background: Blepharospasm is a chronic facial movement disorder affecting a person’s ability to work, causing depression, pain, and a reduced quality of life (QoL). Botulinum toxin type A (BoNT-A) treatment can improve these conditions; however, its cost remains a significant barrier for inclusion of this indication into the Thai National List of Essential Medicine. Objectives: This study aimed to assess the cost-effectiveness of onabotulinumtoxinA (onaBoNT-A) and abobotulinumtoxinA (aboBoNT-A) treatment compared to oral medication treatment in patients with severe blepharospasm from a societal perspective. Methods: A cost-utility analysis using a two-part model was conducted to analyze lifetime costs and quality-adjusted life-years (QALYs). Inputs were mainly obtained from real-world evidence of 159 Thai patients with blepharospasm. Costs and outcomes were discounted at 3% annually and presented as 2023 value. Incremental cost-effectiveness ratios (ICERs) were estimated. Deterministic and probabilistic sensitivity analyses were also conducted. Results: In comparison to standard oral medication, both onaBoNT-A and aboBoNT-A incurred greater lifetime cost (3,055 USD, 2,889 USD vs 1,926 USD) while gaining additional QALYs (6.94 years, 6.94 years vs 6.53 years). The estimated ICERs were 2,722 USD/QALY for onaBoNT-A and 2,323 USD/QALY for aboBoNT-A. Utility and cost of BoNT-A were important determinants in the sensitivity analysis. Conclusion: Among patients with severe blepharospasm, both onaBoNT-A and aboBoNT-A were considered a cost-effective strategy under the Thai willingness to pay threshold of 4,613 USD/QALY. Having aboBoNT-A was slightly more favorable due to lower cost, using a conversion ratio of 1U of onaBoNT-A: 3U of aboBoNT-A.
- Open Access
- 28 June 2024
- Published by Hawaii Pacific University in International Journal of Telerehabilitation
- Vol. 16 (1) , 1-4
Corrections to: Evaluation of Psychometric Properties of Thai Version Telehealth Usability Questionnaire (T-TUQ), International Journal of Telerehabilitation
Corrections to: Parima Hirunwiwatkul, MD, Punnaka Pongpanich, MD, Wasee Tulvatana, MD, Supharat Jariyakosol, MD, Warongporn Phuenpathom, MD, MS, Supaporn Krittanupong, RN, Ruttanabhorn Chonramak, BS, Tidarat Pichedvanichok, BSN, RN, Roongroj Bhidayasiri, MD, FRCP, Chaichana Nimnuan, MD, PhD. Evaluation of Psychometric Properties of Thai Version Telehealth Usability Questionnaire (T-TUQ), International Journal of Telerehabilitation, Vol. 15, No. 2 Fall 2023 • (10.5195/ijt.2023.6577)
- 28 June 2024
- Published by Hawaii Pacific University in International Journal of Telerehabilitation
- Vol. 16 (1) , 1-4
Open AccessCorrections to: Evaluation of Psychometric Properties of Thai Version Telehealth Usability Questionnaire (T-TUQ), International Journal of Telerehabilitation
Corrections to: Parima Hirunwiwatkul, MD, Punnaka Pongpanich, MD, Wasee Tulvatana, MD, Supharat Jariyakosol, MD, Warongporn Phuenpathom, MD, MS, Supaporn Krittanupong, RN, Ruttanabhorn Chonramak, BS, Tidarat Pichedvanichok, BSN, RN, Roongroj Bhidayasiri, MD, FRCP, Chaichana Nimnuan, MD, PhD. Evaluation of Psychometric Properties of Thai Version Telehealth Usability Questionnaire (T-TUQ), International Journal of Telerehabilitation, Vol. 15, No. 2 Fall 2023 • (10.5195/ijt.2023.6577)
- Open Access
- 12 December 2023
- Published by Hawaii Pacific University in International Journal of Telerehabilitation
- Vol. 15 (2) , e6577
Evaluation of Psychometric Properties of Thai Version Telehealth Usability Questionnaire (T-TUQ)
This cross-sectional validation study aimed to translate, cross-culturally adapt, and investigate the psychometric properties of a Thai version of the Telehealth Usability Questionnaire (T-TUQ). Two hundred and ten Thai participants, mean age of 61.2±15.2 years, were recruited from three specialty clinics: 50 (23.8%) hematology, 70 (33.3%) movement disorders, and 90 (42.9%) general neurology. The T-TUQ was translated from the original English version to produce a Thai language version. Back translation and pilot cognitive interviews were completed. All five subscales (usefulness, ease of use, effectiveness, reliability, and satisfaction) showed excellent internal consistency (alpha >0.80), displayed by Cronbach's alpha coefficient of 0.83, 0.94, 0.86, 0.83, and 0.92, respectively. For construct validity, exploratory factor analysis revealed two dimensions from eigenvalues and scree plot, defined as utility and accessibility subscales. In conclusion, the T-TUQ could be a reliable and valid instrument to evaluate the usability of telehealth with a Thai population.
- 12 December 2023
- Published by Hawaii Pacific University in International Journal of Telerehabilitation
- Vol. 15 (2) , e6577
Open AccessEvaluation of Psychometric Properties of Thai Version Telehealth Usability Questionnaire (T-TUQ)
This cross-sectional validation study aimed to translate, cross-culturally adapt, and investigate the psychometric properties of a Thai version of the Telehealth Usability Questionnaire (T-TUQ). Two hundred and ten Thai participants, mean age of 61.2±15.2 years, were recruited from three specialty clinics: 50 (23.8%) hematology, 70 (33.3%) movement disorders, and 90 (42.9%) general neurology. The T-TUQ was translated from the original English version to produce a Thai language version. Back translation and pilot cognitive interviews were completed. All five subscales (usefulness, ease of use, effectiveness, reliability, and satisfaction) showed excellent internal consistency (alpha >0.80), displayed by Cronbach's alpha coefficient of 0.83, 0.94, 0.86, 0.83, and 0.92, respectively. For construct validity, exploratory factor analysis revealed two dimensions from eigenvalues and scree plot, defined as utility and accessibility subscales. In conclusion, the T-TUQ could be a reliable and valid instrument to evaluate the usability of telehealth with a Thai population.
- Open Access
- 4 May 2023
- Published by Springer Nature in Research Square
Reliability and Usability of Telemedicine Evaluations for Facial Dystonia
This study aimed to investigate telemedicine reliability and usability for facial dystonia. Eighty-two telemedicine recordings from 43 adults with blepharospasm (12,27.9%) and hemifacial spasm (31,72.1%) were obtained (mean age 64.5+9.3 years, 32 female (64.4%)). Two recorded in-hospital telemedicine visits were arranged on the same day as in-person visits at baseline and 4-6 weeks. The third non-recorded home-based telemedicine visit was held 2 days prior to the third in-person visit at 12-14 weeks. After 8 weeks, the neuro-ophthalmologists who performed the in-person visits also evaluated the telemedicine videos records. Spasm gradings by Jankovic Rating Scale (low, grades 0-2; high, grades 3-4), signs and symptoms indicating botulinum toxin complications were collected. Intra-rater agreements in assessing spasm gradings were moderate (severity: kappa=0.42, 95%CI 0.21 to 0.62, frequency: kappa=0.41, 95%CI 0.21 to 0.61) with substantial agreement in detecting lagophthalmos (kappa=0.61, 95%CI 0.36 to 0.86). Adding symptoms to signs increased sensitivity and negative predictive value in detecting lagophthalmos (66.7% to 100% and 94.3% to 100%) and drooping lips (37.5% to 75% and 93.6% to 96.4%), respectively. High mean usability score of 6.5(SD0.8) out of 7 was determined by “Thai version Telehealth Usability Questionnaire.” Therefore, telemedicine could be an alternative platform to evaluate facial dystonia.
- 4 May 2023
- Published by Springer Nature in Research Square
Open AccessReliability and Usability of Telemedicine Evaluations for Facial Dystonia
This study aimed to investigate telemedicine reliability and usability for facial dystonia. Eighty-two telemedicine recordings from 43 adults with blepharospasm (12,27.9%) and hemifacial spasm (31,72.1%) were obtained (mean age 64.5+9.3 years, 32 female (64.4%)). Two recorded in-hospital telemedicine visits were arranged on the same day as in-person visits at baseline and 4-6 weeks. The third non-recorded home-based telemedicine visit was held 2 days prior to the third in-person visit at 12-14 weeks. After 8 weeks, the neuro-ophthalmologists who performed the in-person visits also evaluated the telemedicine videos records. Spasm gradings by Jankovic Rating Scale (low, grades 0-2; high, grades 3-4), signs and symptoms indicating botulinum toxin complications were collected. Intra-rater agreements in assessing spasm gradings were moderate (severity: kappa=0.42, 95%CI 0.21 to 0.62, frequency: kappa=0.41, 95%CI 0.21 to 0.61) with substantial agreement in detecting lagophthalmos (kappa=0.61, 95%CI 0.36 to 0.86). Adding symptoms to signs increased sensitivity and negative predictive value in detecting lagophthalmos (66.7% to 100% and 94.3% to 100%) and drooping lips (37.5% to 75% and 93.6% to 96.4%), respectively. High mean usability score of 6.5(SD0.8) out of 7 was determined by “Thai version Telehealth Usability Questionnaire.” Therefore, telemedicine could be an alternative platform to evaluate facial dystonia.
- Open Access
- 15 March 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (3) , e0283111
Health-related quality of life of daily-life-affected benign essential blepharospasm: Multi-center observational study
Purpose: To compare Thais’ health-related quality of life (HRQOL) and severity grading, efficacy and safety in daily-life-affected benign essential blepharospasm (BEB) patients at baseline and after Botulinum toxin type A (BTX-A) treatment. Design: Prospective-observational study. Participants: BEB patients with Jankovic rating scale (JRS) at least 3 in both severity and frequency graded from 14 institutes nationwide were included from August 2020 to June 2021. Methods: Demographic data, HRQOL evaluated by the Thai version of EQ-5D-5L and NEI-VFQ-25 questionnaires, and severity grading score evaluated by Jankovic rating scale (JRS) at baseline, 1, and 3 months after the treatment were collected. The impact of the BTX-A injections and their complications were recorded. Results: 184 daily-life-affected BEB patients were enrolled; 159 patients (86.4%) had complete data with a mean age of 61.40±10.09 years. About 88.05% were female, and 10.1% were newly diagnosed. Most of the patients had bilateral involvement (96.9%) and 12.6% had history of BEB-related accident. After BTX-A treatment, HRQOL improved significantly in 4 dimensions of EQ-5D-5L, except self-care. The EQ_VAS (mean±SD) was 64.54±19.27, 75.13±15.37, 73.8±15.85 (p<0.001) and EQ-5D-5L utility score was 0.748±0.23, 0.824±0.19 and 0.807±0.19 at baseline, 1, 3 months after treatment, respectively. From NEI-VFQ-25, HRQOL also improved in all dimensions, except eye pain. The JRS improved in all patients. Self-reported minor adverse events were 22.6%, which mostly resolved within the first month. Conclusion: Daily-life-affected BEB impacted HRQOL in most dimensions from both generic and visual-specific questionnaires. BTX-A treatment not only decreased disease severity, but also improved quality of life.
- 15 March 2023
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (3) , e0283111
Open AccessHealth-related quality of life of daily-life-affected benign essential blepharospasm: Multi-center observational study
Purpose: To compare Thais’ health-related quality of life (HRQOL) and severity grading, efficacy and safety in daily-life-affected benign essential blepharospasm (BEB) patients at baseline and after Botulinum toxin type A (BTX-A) treatment. Design: Prospective-observational study. Participants: BEB patients with Jankovic rating scale (JRS) at least 3 in both severity and frequency graded from 14 institutes nationwide were included from August 2020 to June 2021. Methods: Demographic data, HRQOL evaluated by the Thai version of EQ-5D-5L and NEI-VFQ-25 questionnaires, and severity grading score evaluated by Jankovic rating scale (JRS) at baseline, 1, and 3 months after the treatment were collected. The impact of the BTX-A injections and their complications were recorded. Results: 184 daily-life-affected BEB patients were enrolled; 159 patients (86.4%) had complete data with a mean age of 61.40±10.09 years. About 88.05% were female, and 10.1% were newly diagnosed. Most of the patients had bilateral involvement (96.9%) and 12.6% had history of BEB-related accident. After BTX-A treatment, HRQOL improved significantly in 4 dimensions of EQ-5D-5L, except self-care. The EQ_VAS (mean±SD) was 64.54±19.27, 75.13±15.37, 73.8±15.85 (p<0.001) and EQ-5D-5L utility score was 0.748±0.23, 0.824±0.19 and 0.807±0.19 at baseline, 1, 3 months after treatment, respectively. From NEI-VFQ-25, HRQOL also improved in all dimensions, except eye pain. The JRS improved in all patients. Self-reported minor adverse events were 22.6%, which mostly resolved within the first month. Conclusion: Daily-life-affected BEB impacted HRQOL in most dimensions from both generic and visual-specific questionnaires. BTX-A treatment not only decreased disease severity, but also improved quality of life.
- 22 October 2021
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 42 (2) , 230-233
Interobserver and Intra-Observer Reliability of Eyelid Tests for Ocular Myasthenia Gravis
Background: Lid fatigability test (LFT), Cogan lid twitch (CLT), and forced eyelids closure test (FECT) are simple clinical screening tests for ocular myasthenia gravis (OMG). However, these tests are subjectively interpreted. We thus evaluated the interobserver and intra-observer reliability of each test. Methods: The 3 eyelid tests were performed in ptotic patients associated with various conditions, including OMG and others. Video clips of all tests were recorded using smartphone with built-in camera in the following order; LFT, CLT, and FECT. All video clips were distributed to 3 neuro-ophthalmologists and 3 general ophthalmologists, who were trained to evaluate the tests using a single standard instruction. After 3 months, all video clips were re-organized for the second evaluation. Interobserver and intra-observer reliability were calculated using Cohens' Kappa coefficient and Fleiss Kappa statistic. Results: The 3 eyelid tests were performed and recorded in 35 patients, which included the diagnosis of OMG, levator muscle dehiscence, partial oculomotor nerve palsy, and Horner syndrome. CLT received moderate-to-substantial interobserver reliability in neuro-ophthalmologist group (Fleiss Kappa 0.77 [95% CI 0.60–0.94] and 0.66 [95% CI 0.46–0.85] in first and second evaluation respectively), but the results varied in general ophthalmologist group (Fleiss Kappa 0.58 [95% CI 0.37–0.79] and 0.54 [95% CI 0.33–0.76] in first and second evaluation respectively). FECT and LFT received lower interobserver reliability in both groups. CLT also received moderate-to-almost perfect intra-observer reliability in neuro-ophthalmologist group (Cohen Kappa 0.55, 0.58, and 0.92), whereas FECT and LFT received lower intra-observer reliability. The intra-observer reliability varied among general ophthalmologists for all 3 eyelid tests. Conclusions: CLT is the most reliable test among the 3 eyelid tests. However, all tests should be interpreted with caution by general ophthalmologists.
- 22 October 2021
- Published by Wolters Kluwer Health in Journal of Neuro-Ophthalmology
- Vol. 42 (2) , 230-233
Interobserver and Intra-Observer Reliability of Eyelid Tests for Ocular Myasthenia Gravis
Background: Lid fatigability test (LFT), Cogan lid twitch (CLT), and forced eyelids closure test (FECT) are simple clinical screening tests for ocular myasthenia gravis (OMG). However, these tests are subjectively interpreted. We thus evaluated the interobserver and intra-observer reliability of each test. Methods: The 3 eyelid tests were performed in ptotic patients associated with various conditions, including OMG and others. Video clips of all tests were recorded using smartphone with built-in camera in the following order; LFT, CLT, and FECT. All video clips were distributed to 3 neuro-ophthalmologists and 3 general ophthalmologists, who were trained to evaluate the tests using a single standard instruction. After 3 months, all video clips were re-organized for the second evaluation. Interobserver and intra-observer reliability were calculated using Cohens' Kappa coefficient and Fleiss Kappa statistic. Results: The 3 eyelid tests were performed and recorded in 35 patients, which included the diagnosis of OMG, levator muscle dehiscence, partial oculomotor nerve palsy, and Horner syndrome. CLT received moderate-to-substantial interobserver reliability in neuro-ophthalmologist group (Fleiss Kappa 0.77 [95% CI 0.60–0.94] and 0.66 [95% CI 0.46–0.85] in first and second evaluation respectively), but the results varied in general ophthalmologist group (Fleiss Kappa 0.58 [95% CI 0.37–0.79] and 0.54 [95% CI 0.33–0.76] in first and second evaluation respectively). FECT and LFT received lower interobserver reliability in both groups. CLT also received moderate-to-almost perfect intra-observer reliability in neuro-ophthalmologist group (Cohen Kappa 0.55, 0.58, and 0.92), whereas FECT and LFT received lower intra-observer reliability. The intra-observer reliability varied among general ophthalmologists for all 3 eyelid tests. Conclusions: CLT is the most reliable test among the 3 eyelid tests. However, all tests should be interpreted with caution by general ophthalmologists.
- 17 November 2018
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 276 (2) , 585-604
The use of steroids to reduce complications after tonsillectomy: a systematic review and meta-analysis of randomized controlled studies
To systemically review and compare the efficacy of intravenous, local, and oral steroids in decreasing post-tonsillectomy pain, nausea, and vomiting, and its risk of causing hemorrhage.
- 17 November 2018
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 276 (2) , 585-604
The use of steroids to reduce complications after tonsillectomy: a systematic review and meta-analysis of randomized controlled studies
To systemically review and compare the efficacy of intravenous, local, and oral steroids in decreasing post-tonsillectomy pain, nausea, and vomiting, and its risk of causing hemorrhage.